{"groups":[{"description":"AZD4877 25 mg (Intravenous (IV), 25mg weekly)","id":"FG000","title":"AZD4877"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"20"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"PI Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"11"}],"type":"Survival follow up stage discontinued"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Disease progression"}],"milestones":[{"achievements":[{"comment":"All dosed patients","groupId":"FG000","numSubjects":"41"}],"type":"STARTED"},{"achievements":[{"comment":"Treatment is not for a fixed period and continues until a discontinuation criterion is met.","groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"41"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Following enrolment there was a screening period of up to 28 days, after which if all inclusion/exclusion criteria were met, patients were dosed with AZD4877.","recruitmentDetails":"Patients were recruited at 23 study sites in 5 countries: United States (7 centers), United Kingdom (6 centers), Germany (5 centers), Canada (3 centers), and Spain (2 centers) between 29 May 2008 and 11 January 2010. 54 participants were enrolled into the study of which 41 participants received at least one dose of study medication."}